Uncategorized

The companies’ financial results will offer a glimpse at the current health of medtech markets.

Backed by Bain Capital, Cardurion Pharmaceuticals will use the Series B funds to advance two assets for heart failure and other cardiovascular conditions.

Asceneuron, which develops small molecules targeting tau protein aggregation, plans to use the funds to advance its Alzheimer’s disease asset into Phase II.

The changes are part of a broader reorganization intended to increase organizational agility and help the agency meet user fee commitments.

The bill would create a special liaison within the Cybersecurity and Infrastructure Security Agency to the HHS that could help coordinate responses during cyber incidents.

To help keep pace with the demand for GLP-1 therapies, CordenPharma has announced a sizeable $980 million investment in its U.S. and European sites.

To improve its reviewers’ understanding of cell and gene therapy manufacturing, the agency has launched a program that will involve a tour of manufacturing facilities and daily workshops for its staffers.

After discontinuing its long-acting insulin product Levemir, Novo has again found itself under legislative scrutiny, with three Democratic senators seeking a sit-down with the pharma.

Vertex has filed a complaint against the Department of Health and Human Services, seeking to make its fertility preservation program available to federally-insured patients needing Casgevy treatment.

La medicina regenerativa, un campo innovador que se centra en la reparación y regeneración de tejidos y órganos dañados, está revolucionando el panorama de la salud. A través de enfoques que van desde la terapia celular hasta la bioingeniería de tejid …